

CURRICULUM VITAE

The Johns Hopkins University School of Medicine

(Signature) _____

(Typed Name) **Eleonora Scorletti, M.D., Ph.D.**

(Date of this version) 10/22/26

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

University

6/26-present Assistant Professor, Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

6/26-present Director of Translational Metabolic Liver Research, Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

Hospital

None

Other

None

Personal Data

Division of Gastroenterology and Hepatology
Department of Medicine
Johns Hopkins University School of Medicine
Ross Research Building, 720 Rutland Avenue
Baltimore, MD 21205
Email: escorle1@jh.edu

Education and Training

Undergraduate

None (combined undergraduate-medical training; see Doctoral/Graduate)

Doctoral/Graduate

2005 M.D., University of Pavia, Pavia, Italy

2018 Ph.D., Nutrition and Liver Metabolism, University of Southampton, Southampton, United Kingdom;
Thesis Advisors: Christopher Byrne and Philip Calder

Postdoctoral

2005-2007 Research Fellow in Medicine, San Matteo University Hospital, Pavia, Italy

2007-2011 Resident, Preventive Medicine, University of Pavia, Pavia, Italy

2011-2014 Research Fellow, Nutrition and Metabolism, National Institute for Health and Care Research (NIHR) Southampton Biomedical Research Centre, University of Southampton, Southampton, United Kingdom; Mentors: Christopher Byrne and Philip Calder

2018-2021 Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Mentor: Rotonya Carr

2021-2023 Postdoctoral Fellow, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Mentor: Daniel J. Rader

Professional Experience

2007-2011 Resident Physician, Preventive Medicine, University of Pavia, Pavia, Italy

2011-2018 Clinical Research Fellow, Nutrition and Metabolism, NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom

2018-2021 Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

2021-2023 Postdoctoral Fellow, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

8/23-5/26 Instructor, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

6/26-present Assistant Professor, Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

PUBLICATIONS**Original Research [OR]**

1. **Scorletti E**, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, Byrne CD; WELCOME Trial Investigators. Design and rationale of the WELCOME trial: a randomized, placebo-controlled study to test the efficacy of purified long-chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease. *Contemp Clin Trials*. 2014;37(2):301-11.
2. **Scorletti E**, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, Moyses HE, Calder PC, Byrne CD; WELCOME Study. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study. *Hepatology*. 2014;60(4):1211-21.
3. McCormick KG, **Scorletti E**, Bhatia L, Calder PC, Griffin MJ, Clough GF, Byrne CD. Impact of high-dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomized WELCOME trial. *Diabetologia*. 2015;58(8):1916-25. *Co-investigator; data analysis, manuscript revision*.
4. **Scorletti E**, West AL, Bhatia L, Hoile SP, McCormick KG, Burdge GC, Lillycrop KA, Clough GF, Calder PC, Byrne CD. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. *J Hepatol*. 2015;63(6):1476-83.
5. Bhatia L, **Scorletti E**, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. *Atherosclerosis*. 2016;246:13-20. *Co-investigator; data analysis, manuscript revision*.
6. Clough GF, McCormick KG, **Scorletti E**, Bhatia L, Calder PC, Griffin MJ, Byrne CD. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomized WELCOME trial. *Diabetologia*. 2016;59(7):1422-9. *Co-investigator; data analysis, manuscript revision*.
7. Hodson L, Bhatia L, **Scorletti E**, Smith DE, Jackson NC, Shojaei-Moradie F, Umpleby M, Calder PC, Byrne CD. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. *Eur J Clin Nutr*. 2017. *Co-investigator; data analysis, manuscript revision*.
8. Nobili V, Alisi A, Mosca A, Della Corte C, Veraldi S, De Vito R, De Stefanis C, D'Oria V, Jahnel J, Zohrer E, **Scorletti E**, Byrne CD. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. *Liver Int*. 2017. *Co-investigator; data analysis, manuscript revision*.
9. Nobili V, Mosca A, De Vito R, Raponi M, **Scorletti E**, Byrne CD. Liver zonation in children with NAFLD: associations with dietary fructose and uric acid concentrations. *Liver Int*. 2017. *Co-investigator; data analysis, manuscript revision*.
10. **Scorletti E**, Afolabi PR, Miles EA, Smith DE, Almeshmadi A, Alshathry A, Moyses HE, Clough GF, Wright M, Patel J, Bindels L, Delzenne NM, Calder PC, Byrne CD. Design and rationale of the INSYTE study: a randomized, placebo-controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. *Contemp Clin Trials*. 2018.
11. Welsh JA, **Scorletti E**, Clough GF, Englyst NA, Byrne CD. Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD. *J Leukoc Biol*. 2018. *Co-investigator; data analysis, manuscript revision*.
12. Afolabi PR, **Scorletti E**, Smith DE, Almeshmadi AA, Calder PC, Byrne CD. The characterization of hepatic mitochondria dysfunction in patients with non-alcoholic fatty liver disease using the 13C-ketosisicaproate breath test. *J Breath Res*. 2018. *Co-investigator; subject recruitment, data analysis*.
13. Manousopoulou A*, **Scorletti E***, Smith DE, Teng J, Fotopoulos M, Roumeliotis TI, Clough GF, Calder PC, Byrne CD, Garbis SD. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: plasma proteomics in the randomized WELCOME trial. *Clin Nutr*. 2018. **Co-first authorship; subject recruitment, data analysis, manuscript writing*.
14. Mosca A, Fintini D, **Scorletti E**, Cappa M, Paone L, Zicari AM, Nobili V, Byrne CD. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents. *Liver Int*. 2018. *Co-investigator; data analysis, manuscript revision*.
15. Chipperfield AJ, Thanaj M, **Scorletti E**, Byrne CD, Clough GF. Multi-domain analysis of microvascular flow motion dynamics in NAFLD. *Microcirculation*. 2019;26(5):e12538. *Co-investigator; data analysis, manuscript revision*.

16. Afolabi PR, **Scorletti E**, Calder PC, Byrne CD. The evaluation of the repeatability of the ¹³C-ketosisicaproate breath test for assessing hepatic mitochondrial function. *Isotopes Environ Health Stud.* 2019;55(2):150-60. *Co-investigator; data analysis, manuscript revision.*
17. Sung KC, Huh JH, Ryu S, Lee JY, **Scorletti E**, Byrne CD, Kim JY, Hyun DS, Ko SB. Low levels of low-density lipoprotein cholesterol and mortality outcomes in non-statin users. *J Clin Med.* 2019;8(10). *Co-investigator; manuscript revision.*
18. Brettschneider J, Correnti JM, Lin C, Williams B, Oranu A, Kuriakose A, McIver-Jenkins D, Haba A, Kaneza I, Jeon S, **Scorletti E**, Carr RM. Rapid lipid droplet isolation protocol using a well-established organelle isolation kit. *J Vis Exp.* 2019;(146). *Co-investigator; experimental data, manuscript revision.*
19. **Scorletti E**, Afolabi PR, Miles EA, Smith DE, Alshathry A, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. *Gastroenterology.* 2020;158(6):1597-610.e7. *First/corresponding author; study design, subject recruitment, data analysis, manuscript writing.*
20. Correnti J, Lin C, Brettschneider J, Kuriakose A, Jeon S, **Scorletti E**, Oranu A, McIver-Jenkins D, Kaneza I, Buyco D, Saiman Y, Furth EE, Argemi J, Bataller R, Holland WL, Carr RM. Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice. *J Lipid Res.* 2020;61(7):983-94. *Co-investigator; experimental data, manuscript revision.*
21. Clough GF, Chipperfield AJ, Thanaj M, **Scorletti E**, Byrne CD. Dysregulated neurovascular control underlies declining microvascular functionality in people with non-alcoholic fatty liver disease at risk of liver fibrosis. *Front Physiol.* 2020;11:551. *Co-investigator; subject recruitment, data analysis, manuscript revision.*
22. Afolabi PR, **Scorletti E**, Calder PC, Byrne CD. Factors independently associated with cardiorespiratory fitness in patients with non-alcoholic fatty liver disease. *Liver Int.* 2020;40(12):2998-3007. *Co-investigator; data analysis, manuscript revision.*
23. Bilson J, **Scorletti E**, Bindels LB, Afolabi PR, Targher G, Calder PC, Sethi JK, Byrne CD. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. *Nutr Diabetes.* 2021;11(1):32. *Co-investigator; data analysis, manuscript revision.*
24. **Scorletti E***, Creasy KT*, Vujkovic M, Vell M, Zandvakili I, Rader DJ, Schneider KM, Schneider CV. Dietary vitamin E intake is associated with a reduced risk of developing digestive diseases and nonalcoholic fatty liver disease. *Am J Gastroenterol.* 2022;117(6):927-30. **Co-first authorship.*
25. Buyco DG, Dempsey JL, **Scorletti E**, Jeon S, Lin C, Harkin J, Bayen S, Furth EE, Martin J, Delima M, Hooks R, Sostre-Colón J, Gharib SA, Titchenell PM, Carr RM. Concomitant western diet and chronic-binge alcohol dysregulate hepatic metabolism. *PLoS One.* 2023;18(5):e0281954. *Co-investigator; experimental data, manuscript revision.*
26. Schneider CV, Hehl L, Creasy KT, Vitali C, Vell MS, Vujkovic M, Park J, **Scorletti E**, Seeling KS, Rendel MD, Conlon DM, Huang H, Zandvakili I, Valmiki S, Regeneron Genetics Center, Schneider KM, Hussain MM, Rader DJ. A coding variant in the microsomal triglyceride transfer protein reduces both hepatic steatosis and plasma lipids. *Aliment Pharmacol Ther.* 2023;58(2):238-49. *Co-investigator; data analysis, manuscript revision.*
27. Vell MS, Creasy KT, **Scorletti E**, Seeling KS, Hehl L, Rendel MD, Schneider KM, Schneider CV. Omega-3 intake is associated with liver disease protection. *Front Public Health.* 2023. *Co-investigator; data analysis, manuscript revision.*
28. Schneider CV, Li T, Zhang D, Mezina AI, Rattan P, Huang H, Creasy KT, **Scorletti E**, Zandvakili I, Vujkovic M, Hehl L, Fiksel J, Park J, Wangenstein K, Risman M, Chang KM, Serper M, Carr RM, Schneider KM, Chen J, Rader DJ. Large-scale identification of undiagnosed hepatic steatosis using natural language processing. *eClinicalMedicine.* 2023. *Co-investigator; data analysis, manuscript revision.*
29. Vell MS, Loomba R, Krishnan A, Wangenstein KJ, Trebicka J, Creasy KT, Trautwein C, **Scorletti E**, Seeling KS, Hehl L, Rendel MD, Zandvakili I, Li T, Chen J, Vujkovic M, Alqahtani S, Rader DJ, Schneider KM, Schneider CV. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. *JAMA Netw Open.* 2023;6(6):e2320222. *Co-investigator; data analysis, manuscript revision.*
30. Vell MS, Krishnan A, Wangenstein K, Serper M, Seeling KS, Hehl L, Rendel MD, Zandvakili I, Vujkovic M, **Scorletti E**, Creasy KT, Trautwein C, Rader DJ, Alqahtani S, Schneider KM, Schneider CV. Aspirin is associated with a reduced incidence of liver disease in men. *Hepatol Commun.* 2023;7(10):e0268. *Co-investigator; data analysis, manuscript revision.*
31. Jeon S, **Scorletti E**, Dempsey J, Buyco D, Lin C, Saiman Y, Bayen S, Harkin J, Martin J, Hooks R, Ogretmen B, Argemi J, Melo L, Bataller R, Carr RM. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver

disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation. *Mol Metab.* 2023;78:101804. *Co-investigator; experimental data, manuscript revision.*

32. **Scorletti E**, Saiman Y, Jeon S, Buyco DG, Schneider CV, Lin C, Himes BE, Mesaros CA, Vujkovic M, Creasy KT, Furth EE, Billheimer JT, Hand NJ, Kaplan DE, Chang KM, Tsao PS, Lynch JA, Dempsey JL, Harkin J, Bayen S, Conlon D, Guerraty M, Phillips MC, Rader DJ, Carr RM. A missense variant in human Perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice. *JHEP Rep.* 2024;6(1):100902. *First/ corresponding author; study design, experimental data, data analysis, manuscript writing.*
33. Bilson J, Oquendo CJ, Read J, **Scorletti E**, Afolabi PR, Lord J, Bindels LB, Targher G, Mahajan S, Baralle D, Calder PC, Byrne CD, Sethi JK. Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD. *Metabolism.* 2024;151:155759. *Co-investigator; data analysis, manuscript revision.*
34. Hehl L, Creasy KT, Vitali C, **Scorletti E**, Seeling KS, Vell MS, Rendel MD, Conlon D, Vujkovic M, Zandvakili I, Trautwein C, Schneider KM, Rader DJ, Schneider CV; Regeneron Genetics Center. A genome-first approach to variants in MLXIPL and their association with hepatic steatosis and plasma lipids. *Hepatol Commun.* 2024;8(5):e0427. *Co-investigator; data analysis, manuscript revision.*
35. Rendel MD, Vitali C, Creasy KT, Zhang D, **Scorletti E**, Huang H, Seeling KS, Park J, Hehl L, Vell MS, Conlon D, Hayat S, Regeneron Genetics Center, Phillips MC, Schneider KM, Rader DJ, Schneider CV. The common p.Ile291Val variant of ERLIN1 enhances TM6SF2 function and is associated with protection against MASLD. *Med.* 2024;5(8):963-980.e5. *Co-investigator; data analysis, manuscript revision.*
36. Huang HYR, Vitali C, Zhang D, Hand NJ, Phillips MC, Creasy KT, **Scorletti E**, Park J, Regeneron Genetics Center, Schneider KM, Rader DJ, Schneider CV. Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach. *JHEP Rep.* 2025;7(1):101243. *Co-investigator; data analysis, manuscript revision.*
37. Bilson J, Hydes TJ, McDonnell D, Buchanan RM, **Scorletti E**, Mantovani A, Targher G, Byrne CD. Impact of metabolic syndrome traits on kidney disease risk in individuals with MASLD: a UK Biobank study. *Liver Int.* 2025;45(4):e16159. *Co-investigator; data analysis, manuscript revision.*

Review Articles [RA]

1. **Scorletti E**, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. *Endocrine.* 2011;40(3):332-43.
2. Targher G, **Scorletti E**, Mantovani A, Byrne CD. Nonalcoholic fatty liver disease and reduced serum vitamin D3 levels. *Metab Syndr Relat Disord.* 2013;11(4):217-28. *Co-author; manuscript writing and revision.*
3. **Scorletti E**, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. *Annu Rev Nutr.* 2013;33:231-48.
4. **Scorletti E**, Byrne CD. Extrahepatic diseases and NAFLD: the triangular relationship between NAFLD, type 2 diabetes and dysbiosis. *Dig Dis.* 2016;34 Suppl 1:11-8.
5. Nobili V, Alisi A, Musso G, **Scorletti E**, Calder PC, Byrne CD. Omega-3 fatty acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. *Crit Rev Clin Lab Sci.* 2016;53(2):106-20. *Co-author; manuscript writing and revision.*
6. Wainwright P, **Scorletti E**, Byrne CD. Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis. *Curr Diab Rep.* 2017;17(4):20. *Co-author; manuscript writing and revision.*
7. Mann J, Valenti L, **Scorletti E**, Byrne CD, Nobili V. Nonalcoholic fatty liver disease in children. *Semin Liver Dis.* 2018;38(1):1-13. *Co-author; manuscript writing and revision.*
8. **Scorletti E**, Byrne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action. *Semin Liver Dis.* 2018;38(1):1-13.
9. **Scorletti E**, Mantovani A, Mosca A, Byrne CD, Alisi A, Targher G. Complications, morbidity and mortality of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Metabolism.* 2020;111S:154170.
10. Mantovani A, Byrne CD, **Scorletti E**, Mantzoros C, Targher G. Efficacy and safety of antihyperglycemic drugs in NAFLD: a systematic review of randomized controlled trials. *Diabetes Metab.* 2020;46(6):427-41. *Co-author; manuscript writing and revision.*
11. **Scorletti E**, Carr RM. A new perspective on NAFLD: focusing on lipid droplets. *J Hepatol.* 2022;76(4):934-45.
12. Bilson J, **Scorletti E**. Lipid droplets in steatotic liver disease. *Curr Opin Clin Nutr Metab Care.* 2024;27(2):91-7. *Senior author; manuscript writing and revision.*
13. Bilson J, **Scorletti E**, Swann JR, Byrne CD. Bile acids as emerging players at the intersection of steatotic liver disease and cardiovascular diseases. *Biomolecules.* 2024;14(7):841. *Co-author; manuscript writing and revision.*

14. Yi-An K*, Fisher G*, **Scorletti E***, et al. Leveraging academic medical biobanks for recall-by-genotype deep phenotyping studies. *Hum Mol Genet.* 2025;1-10. *Co-first authorship.

Book Chapters, Monographs [BC]

1. **Scorletti E**, Byrne CD. NAFLD and cardiovascular disease: clinical implications. In: Bugianesi E, editor. Non-Alcoholic Fatty Liver Disease — A 360-degree Overview. Springer; 2018.

Guidelines/Protocols, Consensus Statement, Expert Opinion, Consortium Articles [GL]

1. Byrne CD, Patel J, **Scorletti E**, Targher G. Tests for the diagnosing and monitoring non-alcoholic fatty liver disease in adults. *BMJ.* 2018. Co-author; manuscript writing and revision.

Letters, Correspondence [LT]

1. Nobili V, Mosca A, **Scorletti E**, Byrne CD. Reply to: "Fructose, uric acid and zonal differences in NASH.". *J Hepatol.* 2017;67(5):1118-9. Co-author; manuscript writing and revision.
2. Nobili V, Mosca A, **Scorletti E**, Byrne CD. Reply to: "Energy drinks and adolescents — a hepatic health hazard?". *J Hepatol.* 2017. Co-author; manuscript writing and revision.

FUNDING

EXTRAMURAL FUNDING

Research Extramural Funding

Current

- | | |
|------------|---|
| 1/26-12/28 | Investigating the role of genetic variants and aging on eicosanoid metabolism in adipose tissue
R21 (NIH-NIA)
NIH/NIA
\$446,875
Role: PI, 20% |
| 6/26-5/29 | The role of lipid droplet proteins in eicosanoid production and non-alcoholic fatty liver disease
R00 (NIH-NIDDK)
NIH/NIDDK
\$747,000
Role: PI, 75% |

Pending

None

Previous

- | | |
|-------------|---|
| 10/08-11/08 | Impact of malnutrition and associated diseases in the population of Ayamé, Côte d'Ivoire
Cariplo Foundation Bank, Italy
£900
Role: PI, 100% |
| 1/11-7/11 | Research Fellowship to conduct research at the Southampton NIHR Biomedical Research Centre
University of Pavia, Italy
£7,000
Role: PI, 100%; Mentors: Christopher Byrne and Philip Calder |
| 7/17-7/18 | Clinical Research Fellowship in Nutrition and Metabolism at the Southampton NIHR Biomedical Research Centre
Parnell Diabetes Trust
~£50,000
Role: PI, 100%; Mentors: Christopher Byrne and Philip Calder |
| 9/20-8/22 | AASLD Afdhal/McHutchison Liver Investigator Funding for Education and Research (LIFER) Award
American Association for the Study of Liver Diseases (AASLD) Foundation
\$100,000
Role: PI, 50% |
| 9/24-5/26 | The role of lipid droplet proteins in eicosanoid production and non-alcoholic fatty liver disease
K99DK137029
NIH/NIDDK
\$180,000
Role: PI, 75% |

INTRAMURAL FUNDING

Research Intramural Funding

Current

None

Pending

None

Previous

9/23-8/24	Junior Investigator Pilot and Feasibility Grant University of Pennsylvania \$20,000 Role: PI, 100%; Mentors: Daniel J. Rader and Garret A. FitzGerald
1/25-5/26	Investigating the impact of GLP1R gene variants on therapeutic response to GLP1R agonists in African American and European populations: a deep phenotyping study Diabetes Research Center (DRC) Pilot and Feasibility Grant Program, University of Pennsylvania \$50,000 Role: PI, 0%

CLINICAL ACTIVITIES

Clinical Focus

Translational physician-scientist with prior clinical practice in metabolic medicine, including outpatient management of patients with type 2 diabetes, obesity, dyslipidemia, and metabolic dysfunction-associated steatotic liver disease (MASLD) in both Italy and the United Kingdom. Clinical practice currently inactive while pursuing full-time research in the United States; clinical insight informs my recall-by-genotype deep phenotyping research program in metabolic disease.

Certification

Medical, other state/government licensure

2026	Pennsylvania, Institutional Medical License
2006-present	Italy, Italian Medical Council (Albo Italiano Medici Chirurghi); license to practice medicine
2011-present	United Kingdom, General Medical Council (GMC); license to practice medicine (registered; license currently inactive)

Boards, other specialty certification

2011-present	Italian Medical Council, Specialist in Preventive Medicine and Public Health
2016-present	General Medical Council of the United Kingdom, Specialist Register of Preventive Medicine and Public Health (registered; currently inactive)

Clinical (Service) Responsibilities

2007-2011	Outpatient Physician, metabolic disease clinic (type 2 diabetes, dyslipidemia, liver steatosis), University of Pavia, Pavia, Italy
2011-2018	Outpatient Physician, metabolic disease clinic (type 2 diabetes, obesity, dyslipidemia, non-alcoholic fatty liver disease), University Hospital Southampton, Southampton, United Kingdom

EDUCATIONAL ACTIVITIES

Educational Focus

My educational focus is on translational training in metabolic disease, integrating recall-by-genotype deep phenotyping with mechanistic induced pluripotent stem cell (iPSC)-based modeling. I mentor trainees in clinical and translational research methodology, study design, IRB navigation, grant writing, and manuscript preparation, with particular attention to the developmental needs of first-generation and underrepresented scientists.

Teaching and Facilitating Learning

Classroom Instruction

JHMI/Regional

None

National

None

International

4/09-6/09	Lecturer, undergraduate Nutrition course, University of Pavia, Pavia, Italy
-----------	---

2/14	Lecturer, "Diabetes," undergraduate Biology students, University of Southampton, Southampton, United Kingdom
11/15	Lecturer, "Obesity, metabolic syndrome and type 2 diabetes," undergraduate Biology students, University of Southampton, Southampton, United Kingdom

Clinical Instruction

JHMI/Regional

None

National

None

International

None

CME Instruction

JHMI/Regional

See Invited Talks

National

See Invited Talks

International

See Invited Talks

Workshops/Seminars

JHMI/Regional

None

National

None

International

None

Mentoring, Coaching, and Advising

Pre-doctoral Advisees/Mentees

1/13-4/13	Charles Palmer, medical student, University of Southampton, Southampton, United Kingdom; clinical research project on omega-3 fatty acid treatment in NAFLD; gained experience in study design, data analysis, and scientific communication
9/16-12/16	Rochelle Arulanandam, medical student, University of Southampton, Southampton, United Kingdom; clinical research project on synbiotic effects in NAFLD; gained experience in study design, data analysis, and scientific communication

Post-doctoral Advisees/Mentees

None to date

Thesis Committees

None

RESEARCH ACTIVITIES

Research Focus

Translational physician-scientist focused on understanding how genetic variation drives disease mechanisms, clinical phenotypes, and therapeutic responses in metabolic disorders. My program leverages a "humans as model organisms" approach, combining recall-by-genotype deep phenotyping, pharmacological perturbation, and patient-derived induced pluripotent stem cell (iPSC)-based modeling to investigate how genetic variants in lipid droplet proteins and metabolic receptors alter cellular physiology, accelerate aging, and determine drug efficacy. Three interconnected projects: (1) genetic variants in lipid droplet proteins (PNPLA3-I148M, PLIN2-Pro251, HSD17B13, MBOAT7) as drivers of cardiometabolic disease and metabolic dysfunction-associated steatotic liver disease (MASLD); (2) gene-aging interactions in adipose tissue eicosanoid production; and (3) glucagon-like peptide-1 receptor (GLP1R) pharmacogenomics and incretin-based therapy response. Findings inform genotype-stratified precision medicine strategies for metabolic disease.

Research Program Building / Leadership

2024-2026	Principal Investigator, Recall-by-Genotype Deep Phenotyping Studies in Lipid Droplet Variant Carriers (PNPLA3-I148M, PLIN2-Pro251), University of Pennsylvania
2025-2026	Principal Investigator, GLP1R Pharmacogenomics Recall-by-Genotype Study, University of Pennsylvania

Research Demonstration Activities to External Audiences

None to date

Inventions, Patents, Copyrights

None

Technology Transfer Activities

None

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

System Innovation Focus

Co-developed methodologies for non-invasive assessment of hepatic mitochondrial function and fecal microbiome assessment in clinical trials, contributing to more efficient and reproducible measurement strategies for metabolic disease research.

System Innovation and Quality Improvement Efforts within JHMI

None

System Innovation and Quality Improvement Efforts outside of JHMI

2017-2018 Co-developer (with Paul Afolabi), 13C-ketoisocaproate (13C-KICA) breath test for non-invasive assessment of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease, NIHR Southampton Biomedical Research Centre, University Hospital Southampton, United Kingdom

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

2023-2026 Member, Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania
2024-2026 Associate Member, Center for Molecular Studies in Digestive and Liver Diseases, University of Pennsylvania
2025-2026 Member, Institute for Diabetes, Obesity & Metabolism, University of Pennsylvania

Editorial Activities

Editorial Board Appointments

2022-present Member, Editorial Board, *Metabolism and Target Organ Damage*

Journal Peer Review Activities

2020-present Scientific Reports
2021-present The Lancet Gastroenterology and Hepatology
2022-present The Lancet
2022-present Metabolism and Target Organ Damage
2023-present Liver International
2023-present Nature Communications

Other Peer Review Activities

2020-2023 Abstract Reviewer, Annual Congress, European Association for the Study of the Liver (EASL)

Advisory Committees, Review Groups/Study Sections

None

Professional Societies

2018-present Member, American Association for the Study of Liver Diseases (AASLD)
2020-present Member, European Association for the Study of the Liver (EASL)
2022-present Member, American Gastroenterological Association (AGA)

Conference Organizer

JHMI/Regional

None

National

None

International

None

Session Chair

JHMI/Regional

None

National

None

International

None

Consultantships

None

RECOGNITION

Awards, Honors

2008	Cariplo Foundation Bank Research Project Funding, Italy
2011	University of Pavia Research Fellowship, Italy
2017-2018	Parnell Diabetes Trust Clinical Research Fellowship in Nutrition and Metabolism, United Kingdom
2020-2022	AASLD Afdhal/McHutchison LIFER Award, American Association for the Study of Liver Diseases Foundation
2023	Abstract Award, Penn Obesity Symposium, University of Pennsylvania
2024	Edward Holmes Clinical Research Award for Early Career Faculty, Department of Medicine Research Day, Perelman School of Medicine, University of Pennsylvania
2024	NIH Pathway to Independence Award (K99/R00), NIH/NIDDK
2026	NIH-NIA R21 Award (1st percentile, Impact Score 20)

Invited Talks

JHMI/Regional

2025	"Genetic variation in lipid droplet proteins and metabolic receptors: implications for metabolic disease and precision medicine," Division of Gastroenterology and Hepatology Seminar, Johns Hopkins University School of Medicine, Baltimore, MD
------	---

National

11/20	"Perilipin 2 S251 polymorphism is associated with liver lipid droplets accumulation," 20th Annual Retreat, NIH Center for Molecular Studies in Digestive and Liver Diseases, Philadelphia, PA
2026	"Genetic variation in lipid droplet proteins and metabolic receptors: implications for metabolic disease and precision medicine," Naomi Berrie Diabetes Center Seminar, Columbia University, New York, NY
2026	"Genetic variation in lipid droplet proteins and metabolic receptors: implications for metabolic disease and precision medicine," Division of Gastroenterology, Hepatology and Nutrition Seminar, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2026	"Genetic variation in lipid droplet proteins and metabolic receptors: implications for metabolic disease and precision medicine," Holman Division of Endocrinology, Diabetes, and Metabolism Seminar, NYU Langone Health, New York, NY

International

2011	"Diet and NAFLD: are soft drinks sweet for the liver?" Endocrinology, Nutrition & Metabolism & Cardiovascular Seminar, University of Southampton, Southampton, United Kingdom
2013	"Are long-chain omega-3 fatty acids a treatment for non-alcoholic fatty liver disease?" The Rank Prize Funds Symposium, United Kingdom
2014	"Benefits of docosahexaenoic acid tissue enrichment in non-alcoholic fatty liver disease: results from the randomized double-blind placebo-controlled WELCOME study," Diabetes UK Annual Professional Conference, United Kingdom
2016	"The association of insulin resistance and the PNPLA3 G allele variant with high liver fat," Diabetes UK Annual Professional Conference, United Kingdom
2016	"Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the WELCOME study," Faculty of Medicine Research Conference, University of Southampton, Southampton, United Kingdom
2018	"Omega-3 fatty acids: their role in cardiovascular prevention," 86th European Atherosclerosis Society (EAS) Congress, Lisbon, Portugal

- | | |
|------|--|
| 2024 | "Association of a glucagon-like peptide-1 receptor (GLP-1R) gene variant with cardiometabolic diseases," Keystone Symposia: MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics |
| 2025 | "Targeting lipid metabolism for SLD precision therapy," Faculty Invited Talk, Future of Hepatology Session, EASL Congress, Amsterdam, The Netherlands |

Visiting Professorships

None

OTHER PROFESSIONAL ACCOMPLISHMENTS

Posters

- | | |
|-------|--|
| 11/20 | Scorletti E , et al. "Perilipin 2 S251 polymorphism is protective." American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2020, virtual |
| 2025 | Scorletti E , et al. "Recall-by-genotype and deep phenotyping of homozygous carriers of PNPLA3-I148M without clinical liver disease." Keystone Symposia: MASH Pathogenesis and Therapeutic Approaches (Joint with Obesity and Adipose Tissue), 2025 |

Oral/Podium Presentations

- | | |
|------|--|
| 2024 | Scorletti E , et al. "Differential impacts of GLP1R gene variants on disease risk and treatment efficacy in African American population." American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 |
| 2024 | Scorletti E , et al. "Differential impacts of GLP1R gene variants on disease risk and treatment efficacy in African American population." Digestive Disease Week (DDW), 2024 |

Humanitarian Activities

- | | |
|-----------|---|
| 2000-2005 | Volunteer, Danelli Foundation, providing housing and education services to people living with disabilities, Italy |
| 10/09 | Clinical care for patients with nutritional pathologies, Hôpital Général d'Ayamé, Côte d'Ivoire |

Other

NCBI MyBibliography: <https://www.ncbi.nlm.nih.gov/myncbi/eleonora.scorletti.2/bibliography/public/>